SG 001 - ADMA Biologics
Alternative Names: Anti-pneumococcal immune globulin - ADMA Biologics; S pneumonia immune globulin - ADMA Biologics; S. pneumonia hyperimmune globulin - ADMA Biologics; SG-001 - ADMA Biologics; Streptococcus pneumonia immune globulin - ADMA BiologicsLatest Information Update: 21 Jan 2026
At a glance
- Originator ADMA Biologics
- Class Antibacterials; Immunoglobulins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Pneumococcal infections
Most Recent Events
- 12 Jan 2026 ADMA Biologics announces intention to submit a pre-IND application to FDA for Pneumococcal infections, in 2026
- 12 Jan 2026 ADMA Biologics plans a registrational clinical trial for Pneumococcal infections (Parenteral)
- 05 Nov 2025 ADMA Biologics submits Commissioner’s National Priority Voucher (CNPV) application to the US FDA for SG 001